2. Search Result
Search Result
Results for "

adipogenic differentiation

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

4

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12756A
    E6446 dihydrochloride
    1 Publications Verification

    		 Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD) Metabolic Disease Inflammation/Immunology
    E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
    E6446 dihydrochloride
  • HY-12756
    E6446
    1 Publications Verification

    		 Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD) Metabolic Disease Inflammation/Immunology
    E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
    E6446
  • HY-77641
    Cinnamoylglycine

    		Endogenous Metabolite Metabolic Disease
    Cinnamoylglycine is a human urinary metabolite and PPG analog. Cinnamoylglycine is a conjugate of cinnamic acid and glycine. Cinnamoylglycine is used as a urine marker. Cinnamoylglycine can be used in adipogenic differentiation studies .
    Cinnamoylglycine
  • HY-N2357
    Eudesmin

    (-)-Eudesmin; Eudesmine; (-)-Eudesmine

    		 Ribosomal S6 Kinase (RSK) Infection Metabolic Disease Inflammation/Immunology Cancer
    Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities .
    Eudesmin
  • HY-N0704
    Agrimol B
    1 Publications Verification

    		 Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial Infection Metabolic Disease Cancer
    Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27 .
    Agrimol B
  • HY-123503
    Salicortin

    		JNK NF-κB Neurological Disease Inflammation/Immunology
    Salicortin, a phenolic glycoside, has been isolated from many plants such as Populus and Salix species. Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating JNK and NF-κB/NFATc1 signaling pathways. Salicortin has anti-amnesic, anti-adipogenic, and immune-modulatory activity .
    Salicortin
  • HY-170581
    PPARγ/δ modulator 2

    		PPAR Metabolic Disease
    PPARγ/δ modulator 2 (Compound 3h) is a PPARγ agonist and PPARδ antagonist. The Ki values for PPARγ and PPARδ are 2.8 μM and 43 nM, respectively. PPARγ/δ modulator 2 significantly enhances the production of Adiponectin and promotes adipogenic differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs). PPARγ/δ modulator 2 can be used in the study of metabolic disorders associated with hypoadiponectinemia .
    PPARγ/δ modulator 2
  • HY-172901
    AMPK activator 17

    		AMPK Cardiovascular Disease Metabolic Disease
    AMPK activator 17 (Compound 10g) is an orally active AMPK activator. AMPK activator 17 has significant anti-adipogenic (IC50: 3.4 μM) and dyslipidemia-modifying activities. AMPK activator 17 inhibits the early stages of adipocyte differentiation (mitotic clonal expansion) by activating the AMPK pathway. AMPK activator 17 can enhance mitochondrial function and fatty acid oxidation in mature adipocytes. AMPK activator 17 improves dyslipidemia by promoting reverse cholesterol transport. AMPK activator 17 can be used in the study of obesity and related metabolic diseases (such as type 2 diabetes and cardiovascular disease) .
    AMPK activator 17

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: